Skip to main content
Not investment advice. Educational platform. See Disclaimer.
NASDAQ: SUPN

Supernus Pharmaceuticals, Inc.

Healthcare | Drug Manufacturers - Specialty & Generic

No licensed closing price on file for SUPN. This page shows the company’s SEC filings and filed figures, without a price or any ratio that depends on one.

EPS (TTM)$-1.92

Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) is a specialty and generic drug manufacturer. Figures from SEC EDGAR; updated 2026-10-20 07:47 UTC.

What Supernus Pharmaceuticals, Inc. does

Supernus Pharmaceuticals is a biopharmaceutical company that develops and commercializes medicines for central nervous system diseases, including approved treatments for attention-deficit hyperactivity disorder, Parkinson's Disease complications, postpartum depression, epilepsy, migraine, cervical dystonia, and chronic sialorrhea. The company was incorporated in Delaware and became publicly traded on the NASDAQ under ticker symbol SUPN, with principal offices in Rockville, Maryland.

Summarized from Supernus Pharmaceuticals, Inc.’s SEC filings · AI-generated analysis. Not investment advice. May contain errors. · Read the filing ↗

Pre-revenue, development-stage company: standard profitability ratios (P/E, EV/EBITDA, ROE) do not apply yet because there are no earnings. Watch cash, cash runway, net loss, R&D spend and share dilution instead.

Key facts

Valuation
EPS (TTM)$-1.92

Revenue, margins & earnings

FY2021 Net income: $53MFY2021 Taxes & interest: $33MFY2021 Operating costs: $494M$580MFY2021FY2022 Revenue: $667M — margin split not shown (non-operating gains)$667MFY2022FY2023 Revenue: $608M — margin split not shown (non-operating gains)$608MFY2023FY2024 Net income: $74MFY2024 Taxes & interest: $8MFY2024 Operating costs: $580M$662MFY2024FY2025: net loss $39M on revenue $719M$719MFY2025
  • Net income
  • Taxes & interest
  • Operating costs
  • Net loss year
Annual revenue; bands show net, operating margins · Open in Platform →

SEC Filings

SEC EDGAR ↗
Recent Insider Activity (last 90 days)
Source: SEC EDGAR · Filed 2026-08-14
  • 2026-08-14Senior Vice-President & CFOOption exercise1,250—
  • 2026-08-14Senior Vice-President & CFOPerformance Share UnitOption exercise-1,250—
  • 2026-08-14Sr. VP of IP, CSOOption exercise2,500—
Sign in to see all transactions →
Recent 8-K Events (parsed from SEC filings)All events →
Source: SEC EDGAR 8-K filings · Interpretation: Oxford Ledge parser · Confidence-filtered ≥ 0.50

Company news

View all →

Questions this page answers

What does Supernus Pharmaceuticals, Inc. do?

Supernus Pharmaceuticals, Inc. is a specialty and generic drug manufacturer, listed on NASDAQ as SUPN.

When did SUPN last file with the SEC?

Supernus Pharmaceuticals, Inc.'s most recent SEC filing on record is a 8-K filed 2026-06-18. All filings link to their SEC EDGAR originals above.

Where does this data come from?

SEC EDGAR filings, with the company profile (sector, industry, exchange) from public data providers, fetched 2026-10-20 07:47 UTC. This page is also available as JSON at /api/data?ticker=SUPN and is emitted with FAQPage structured data for machine reading.

For you

Charts, 10-year financials, peer comparison, screening and portfolio tracking for SUPN and 5,000+ tickers.

Create a free account — keep SUPN
For your agent
GET /api/data?ticker=SUPN

This page as JSON via rel="alternate" · REST API docs · MCP server (60 tools) · llms.txt